// STATE LEGISLATION TRACKER

California SB 418: Health care coverage: prescription hormone therapy and nondiscrimination.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Vetoed

State: California
Bill: SB 418
Session: 20252026
Filed: 2025-02-18
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

California SB418 would have required coverage and dispensing of up to a 12-month supply of FDA-approved prescription hormone therapy and self-administration supplies, with nondiscrimination rules for health plans. It does not appear to change compounded peptide access, 503A/503B compounding, telehealth prescribing, NP or naturopath scope, or prescription monitoring; the bill was vetoed and the veto was sustained.

Key Points

No new access pathway for compounded peptides
GLP-1 drugs and GLP-1 receptor agonists were excluded
No change to 503A or 503B compounding rules
No telehealth, NP, or naturopath scope expansion
Controlled hormone drugs stayed limited by existing law
Because veto was sustained, it is not law

What to Watch For

Note Similar hormone-access bills could return in a future California session.

Note The bill was hormone-coverage focused, not peptide-compounding focused.

Concern Its explicit GLP-1 exclusion shows lawmakers may separate peptide-like metabolic drugs from hormone access reforms.

Where the Bill Stands

SB418 passed the Legislature, was vetoed, and the veto was sustained on March 2, 2026, so it did not become law.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws